You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧翔藥業(603229.SH):將出資200萬美元持有英派藥業公司1%股權
格隆匯 11-27 17:05

格隆匯 11 月 27日丨奧翔藥業(603229.SH)公佈,為滿足公司海外市場未來長期的業務發展需求,進一步擴大醫藥產業佈局,實現公司戰略發展目標和提升公司的持續競爭力,公司全資子公司奧翔香港公司與英派藥業公司於20201127日簽訂了《認購協議》,奧翔香港公司將出資200萬美元,持有英派藥業公司1%股權。

鑑於英派藥業公司為2020121日新設公司,尚未開展經營活動,故無相關財務數據。南京英派藥業有限公司(“南京英派公司”)為英派藥業公司的控股孫子公司,英派藥業公司通過南京英派公司開展具體業務。南京英派公司成立於20096月,其以合成致死(Synthetic lethality)和DNA損傷修復(DNA Damage ResponseDDR)藥物自主研發平台,正在構建全球生物技術公司中覆蓋面最廣的DDR產品組合,並且正在逐步拓展到更多的合成致死新靶點。公司產品管線包括PARP抑制劑(IMP4297)、Weel抑制劑(IMP7068)、其DDR靶點抑制劑及Hedgehog通路抑制劑(IMP5471)。其所有品種均為自主研發,擁有全球權益,最成熟的研發項目PARP抑制劑IMP4297是化藥1.1類新藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account